Reported Earnings • May 11
First quarter 2026 earnings released: EPS: €0.035 (vs €0.17 in 1Q 2025) First quarter 2026 results: EPS: €0.035 (down from €0.17 in 1Q 2025). Revenue: €58.7m (down 6.8% from 1Q 2025). Net income: €830.4k (down 79% from 1Q 2025). Profit margin: 1.4% (down from 6.4% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. New Risk • Apr 20
New major risk - Revenue size The company makes less than US$1m in revenue. This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.4% average weekly change). Upcoming Dividend • Apr 13
Upcoming dividend of €0.16 per share Eligible shareholders must have bought the stock before 20 April 2026. Payment date: 22 April 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Italian dividend payers (4.6%). Higher than average of industry peers (0.8%). Declared Dividend • Mar 19
Dividend increased to €0.16 Dividend of €0.16 is 14% higher than last year. Ex-date: 20th April 2026 Payment date: 22nd April 2026 Dividend yield will be 2.0%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 6.9% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 83% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • Mar 18
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Mar 16
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: €61.0m (up 12% from 3Q 2024). Net income: €2.22m (up 3.6% from 3Q 2024). Profit margin: 3.6% (down from 3.9% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 4 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Major Estimate Revision • Mar 16
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €287.0m to €270.7m. EPS estimate also fell from €0.684 per share to €0.588 per share. Net income forecast to grow 13% next year vs 28% growth forecast for Life Sciences industry in Italy. Consensus price target broadly unchanged at €13.00. Share price fell 21% to €8.96 over the past week. New Risk • Mar 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to €9.10, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 19x in the Life Sciences industry in Europe. Total returns to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €9.53 per share. Buy Or Sell Opportunity • Feb 16
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 22% to €11.00. The fair value is estimated to be €9.12, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. Buy Or Sell Opportunity • Jan 12
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 4.1% to €9.54. The fair value is estimated to be €7.92, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 8.7% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. Buy Or Sell Opportunity • Dec 12
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 12% to €9.84. The fair value is estimated to be €8.05, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. Buy Or Sell Opportunity • Nov 25
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 9.9% to €9.56. The fair value is estimated to be €7.94, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 9.3% per annum. Earnings are also forecast to grow by 22% per annum over the same time period. Reported Earnings • Nov 10
Third quarter 2025 earnings released Third quarter 2025 results: Revenue: €61.9m (up 14% from 3Q 2024). Net income: €2.22m (up 3.6% from 3Q 2024). Profit margin: 3.6% (down from 3.9% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Reported Earnings • Aug 06
Second quarter 2025 earnings released: EPS: €0.19 (vs €0.067 in 2Q 2024) Second quarter 2025 results: EPS: €0.19 (up from €0.067 in 2Q 2024). Revenue: €65.7m (up 15% from 2Q 2024). Net income: €4.72m (up 186% from 2Q 2024). Profit margin: 7.2% (up from 2.9% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • May 09
First quarter 2025 earnings released First quarter 2025 results: Revenue: €63.3m (down 3.5% from 1Q 2024). Net income: €4.04m (up 43% from 1Q 2024). Profit margin: 6.4% (up from 4.3% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Announcement • May 09
Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) announces an Equity Buyback for 2,000,000 shares, representing 9.1% for €26 million. Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) announces a share repurchase program. Under the program, the company will repurchase up to 2,000,000 shares, representing 9.1% of issued share for €26 million. The program will be valid for 18 months. Upcoming Dividend • Apr 21
Upcoming dividend of €0.14 per share Eligible shareholders must have bought the stock before 28 April 2025. Payment date: 30 April 2025. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 2.0%. Lower than top quartile of Italian dividend payers (5.8%). Higher than average of industry peers (0.8%). Announcement • Mar 19
Fine Foods & Pharmaceuticals N.T.M. S.p.A., Annual General Meeting, Apr 17, 2025 Fine Foods & Pharmaceuticals N.T.M. S.p.A., Annual General Meeting, Apr 17, 2025, at 15:30 W. Europe Standard Time. Announcement • Mar 18
Fine Foods & Pharmaceuticals N.T.M. S.p.A. announces Annual dividend, payable on April 30, 2025 Fine Foods & Pharmaceuticals N.T.M. S.p.A. announced Annual dividend of EUR 0.1400 per share payable on April 30, 2025, ex-date on April 28, 2025 and record date on April 29, 2025. New Risk • Mar 17
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.1% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 14
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €54.4m (down 6.6% from 3Q 2023). Net income: €2.14m (up €2.24m from 3Q 2023). Profit margin: 3.9% (up from net loss in 3Q 2023). New Risk • Mar 14
New major risk - Revenue and earnings growth Earnings have declined by 28% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Reported Earnings • Nov 17
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: €55.1m (down 5.3% from 3Q 2023). Net income: €2.14m (up €2.24m from 3Q 2023). Profit margin: 3.9% (up from net loss in 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. New Risk • Nov 15
New major risk - Revenue and earnings growth Earnings have declined by 42% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Sep 15
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €57.8m (down 6.7% from 2Q 2023). Net income: €1.65m (up €6.22m from 2Q 2023). Profit margin: 2.9% (up from net loss in 2Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Buy Or Sell Opportunity • May 31
Now 20% undervalued Over the last 90 days, the stock has risen 1.3% to €8.70. The fair value is estimated to be €10.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Upcoming Dividend • May 27
Upcoming dividend of €0.12 per share Eligible shareholders must have bought the stock before 03 June 2024. Payment date: 05 June 2024. The company is not currently making a profit but it is cash flow positive. Trailing yield: 1.4%. Lower than top quartile of Italian dividend payers (5.3%). Higher than average of industry peers (0.7%). Reported Earnings • May 19
First quarter 2024 earnings released First quarter 2024 results: Revenue: €65.8m (flat on 1Q 2023). Net income: €2.82m (down 3.0% from 1Q 2023). Profit margin: 4.3% (down from 4.4% in 1Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Buy Or Sell Opportunity • May 04
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.9% to €8.52. The fair value is estimated to be €10.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.9% over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Mar 30
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: €0.14 loss per share (improved from €0.37 loss in FY 2022). Revenue: €252.9m (up 22% from FY 2022). Net loss: €3.52m (loss narrowed 63% from FY 2022). Revenue exceeded analyst estimates by 2.2%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 92 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 17
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: €59.6m (up 13% from 3Q 2022). Net loss: €97.1k (loss narrowed 98% from 3Q 2022). Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Reported Earnings • Sep 15
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: €63.0m (up 27% from 2Q 2022). Net loss: €4.57m (loss widened 29% from 2Q 2022). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. New Risk • Sep 14
New major risk - Revenue and earnings growth Earnings have declined by 60% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Announcement • Jul 12
Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) commences an Equity Buyback Plan for 20% of its issued share capital,under the authorization approved on May 9, 2023. Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) commences share repurchases on July 3, 2023, under the program mandated by the shareholders in the Ordinary Shareholder's Meeting held on May 9, 2023. As per the mandate, the company is authorized to repurchase up to 20% of its issued share capital, such that company's ordinary shares held from time to time held in the portfolio by the same and by, if any, companies controlled by it, does not exceed a total of 20% of the total share capital of the company. The purchase price per share must be neither lower nor higher than beyond 15% compared to the official stock exchange price of the registered by Borsa Italiana SpA in the previous session or every single transaction. The program will be funded out of distributable profits and available reserves. The repurchased shares will be disposed off in future or share incentive plans also free of charge, exchange for consideration on the occasion of capital transactions. The purpose of the program is stabilization, liquidity support and market efficiency, to obtain a securities portfolio ("securities stock") to be used for any extraordinary transactions, including exchanges of equity investments with other parties, including any bonds convertible into company shares or bonds with warrants, and dividends in shares. The authorization is valid for 18 months. As of March 30, 2023, the company had 22,060,125 ordinary shares in issue of which As of April 28, 2023, the company had 1,033,043 are treasury shares.
On May 15, 2023, the company announced a share repurchase program. Under the program, the company will repurchase 2,000,000 shares, representing 9.1% of its issued share capital for €26 million. The company will subsequently dispose the bought shares. The repurchase program is valid for 18 months. Reported Earnings • May 16
First quarter 2023 earnings released First quarter 2023 results: Revenue: €65.8m (up 29% from 1Q 2022). Net income: €2.91m (up €5.39m from 1Q 2022). Profit margin: 4.4% (up from net loss in 1Q 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. Upcoming Dividend • May 15
Upcoming dividend of €0.10 per share at 1.3% yield Eligible shareholders must have bought the stock before 22 May 2023. Payment date: 24 May 2023. The company is not currently making a profit and is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Italian dividend payers (5.3%). Higher than average of industry peers (0.7%). Board Change • Nov 16
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Chiara Medioli is the most experienced director on the board, commencing their role in 2021. Independent Director Susanna Pedretti was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Major Estimate Revision • Nov 09
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -€0.24 to -€0.35 per share. Revenue forecast unchanged at €207.4m. Life Sciences industry in Italy expected to see average net income growth of 23% next year. Consensus price target down from €13.00 to €11.50. Share price rose 3.8% to €7.98 over the past week. Price Target Changed • Nov 08
Price target decreased to €11.50 Down from €13.00, the current price target is an average from 2 analysts. New target price is 49% above last closing price of €7.70. Stock is down 56% over the past year. The company is forecast to post a net loss per share of €0.35 next year compared to a net loss per share of €0.06 last year. Reported Earnings • Sep 17
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: €49.9m (up 3.2% from 2Q 2021). Net loss: €3.41m (loss narrowed 42% from 2Q 2021). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Reported Earnings • May 16
First quarter 2022 earnings: Revenues in line with analyst expectations First quarter 2022 results: Revenue: €50.9m (up 2.4% from 1Q 2021). Net loss: €2.48m (loss narrowed 23% from 1Q 2021). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 9.8%, compared to a 12% growth forecast for the industry in Italy. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Upcoming Dividend • May 16
Upcoming dividend of €0.16 per share Eligible shareholders must have bought the stock before 23 May 2022. Payment date: 25 May 2022. The company is not currently making a profit and is not cash flow positive. Trailing yield: 2.0%. Lower than top quartile of Italian dividend payers (4.7%). Higher than average of industry peers (0.7%). Price Target Changed • Apr 27
Price target decreased to €14.25 Down from €20.50, the current price target is an average from 2 analysts. New target price is 82% above last closing price of €7.83. Stock is down 40% over the past year. The company is forecast to post earnings per share of €0.22 next year compared to a net loss per share of €0.06 last year. Board Change • Apr 27
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Chiara Medioli is the most experienced director on the board, commencing their role in 2021. Independent Director Susanna Pedretti was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Apr 16
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: €0.06 loss per share (down from €0.58 profit in FY 2020). Revenue: €194.7m (up 10% from FY 2020). Net loss: €1.43m (down 111% from profit in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%. Over the next year, revenue is forecast to grow 6.4%, compared to a 25% growth forecast for the pharmaceuticals industry in Italy. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Buying Opportunity • Mar 31
Now 30% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be €16.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Announcement • Nov 27
Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) made an offer to acquire an additional 24.94% stake in Euro Cosmetic Spa (BIT:EC) for €10.2 million. Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) made an offer to acquire an additional 24.94% stake in Euro Cosmetic Spa (BIT:EC) for €10.2 million on November 26, 2021. As per the transaction, Fine Foods & Pharmaceuticals N.T.M. S.p.A. made the offer to acquire 1.187 million shares at €8.60 per share. The offer period will commence from November 29, 2021 to December 17, 2021 and payment will be made on December 22, 2021. Price Target Changed • Nov 16
Price target decreased to €20.50 Down from €23.00, the current price target is an average from 2 analysts. New target price is 26% above last closing price of €16.30. Stock is up 53% over the past year. The company is forecast to post earnings per share of €0.20 for next year compared to €0.58 last year. Reported Earnings • Nov 14
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €45.6m (down 9.4% from 3Q 2020). Net income: €3.58m (down 30% from 3Q 2020). Profit margin: 7.8% (down from 10% in 3Q 2020). Announcement • Sep 23
Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) signed a binding agreement to acquire a 72.9% stake in Euro Cosmetic S.p.A. (BIT:EC) from Findea's Srl and MD S.R.L. for €26.8 million. Fine Foods & Pharmaceuticals N.T.M. S.p.A. (BIT:FF) signed a binding agreement to acquire a 72.9% stake in Euro Cosmetic S.p.A. (BIT:EC) from Findea's Srl and MD S.R.L. for €26.8 million on September 21, 2021. Fine Foods will acquire 38.7% stake from MD S.R.L. at a price of €8.13 per share for a total of €15 million and 34.2% stake from Findea's Srl at a price of €7.25 per share for a total of €11.8 million. Reported Earnings • Sep 17
First half 2021 earnings released: €0.26 loss per share The company reported a mediocre first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €99.5m (up 31% from 1H 2020). Net loss: €6.47m (down 236% from profit in 1H 2020). Price Target Changed • Sep 02
Price target increased to €18.50 Up from €14.90, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of €18.35. Stock is up 68% over the past year. Upcoming Dividend • Apr 26
Upcoming dividend of €0.14 per share Eligible shareholders must have bought the stock before 03 May 2021. Payment date: 05 May 2021. Trailing yield: 1.0%. Lower than top quartile of Italian dividend payers (4.0%). Higher than average of industry peers (0.5%). Reported Earnings • Apr 24
Full year 2020 earnings released: EPS €0.58 (vs €0.12 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €176.6m (up 9.7% from FY 2019). Net income: €13.4m (up €16.2m from FY 2019). Profit margin: 7.6% (up from net loss in FY 2019). Price Target Changed • Apr 19
Price target increased to €15.50 Up from €14.40, the current price target is an average from 2 analysts. New target price is 20% above last closing price of €12.90. Stock is up 21% over the past year. Price Target Changed • Apr 07
Price target increased to €14.90 Up from €13.50, the current price target is an average from 2 analysts. New target price is 20% above last closing price of €12.40. Stock is up 20% over the past year. Major Estimate Revision • Apr 07
Consensus EPS estimates fall to €0.52 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €215.8m to €213.1m. EPS estimate also fell from €0.59 to €0.52. Net income forecast to shrink 10% next year vs 28% growth forecast for Life Sciences industry in Italy . Consensus price target of €14.40 unchanged from last update. Share price rose 4.6% to €12.40 over the past week. Reported Earnings • Apr 04
Full year 2020 earnings released: EPS €0.58 (vs €0.34 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €177.0m (up 9.8% from FY 2019). Net income: €13.4m (up 120% from FY 2019). Profit margin: 7.6% (up from 3.8% in FY 2019). Announcement • Mar 14
Fine Foods & Pharmaceuticals N.T.M. S.p.A. to Report Fiscal Year 2020 Results on Apr 12, 2021 Fine Foods & Pharmaceuticals N.T.M. S.p.A. announced that they will report fiscal year 2020 results on Apr 12, 2021 Price Target Changed • Dec 10
Price target raised to €13.50 Up from €12.27, the current price target is an average from 2 analysts. The new target price is 26% above the current share price of €10.70. As of last close, the stock is down 9.3% over the past year. Is New 90 Day High Low • Nov 27
New 90-day high: €11.30 The company is up 3.0% from its price of €11.00 on 28 August 2020. The Italian market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €7.14 per share. Is New 90 Day High Low • Oct 19
New 90-day low: €9.76 The company is down 14% from its price of €11.30 on 21 July 2020. The Italian market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.95 per share. Reported Earnings • Oct 01
First half earnings released Over the last 12 months the company has reported total profits of €5.97m, down 34% from the prior year. Total revenue was €153.4m over the last 12 months, largely unchanged from the prior year. Is New 90 Day High Low • Sep 22
New 90-day low: €10.45 The company is down 4.0% from its price of €10.90 on 24 June 2020. The Italian market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €5.97 per share.